Nordson posted record fiscal Q1 2026 results, with sales of USD 669.46 million (+9% YoY) and net income of USD 133.38 million, or USD 2.38 per diluted share (+44% YoY). Adjusted EPS was USD 2.37 (+15% YoY), while EBITDA was USD 202.99 million (30% of sales; +8% YoY). The quarter included a non-cash gain on a minority technology investment, and sales reflected 7% organic growth and a 4% favorable currency impact, partly offset by the prior divestiture of its medical contract manufacturing business. By segment, Industrial Precision Solutions sales were USD 326.86 million (+9% YoY), Medical and Fluid Solutions sales were USD 193.18 million (flat YoY), and Advanced Technology Solutions sales were USD 149.42 million (+23% YoY), driven by growth in electronics dispense systems and recovering demand for x-ray systems. Nordson said backlog rose about 4% YoY and raised full-year guidance, now expecting FY 2026 sales of USD 2.86 billion to USD 2.98 billion and adjusted EPS of USD 11.00 to USD 11.60; it forecast fiscal Q2 2026 sales of USD 710 million to USD 740 million and adjusted EPS of USD 2.70 to USD 2.90.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nordson Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202602181630BIZWIRE_USPR_____20260218_BW403558) on February 18, 2026, and is solely responsible for the information contained therein.